Phenobarbital Sodium Injection (Vitae) – Sterility Concerns (2022)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
PHENOBARBITAL Sodium Injection, USP, 65mg/mL, packaged as a) 25 x 1 mL Vials per box (NDC 42494-415-25) and b) 3 x 1 mL Vials per box (NDC 42494-415-03), Rx only, Manufactured for Cameron Pharmaceuticals, LLC.
Brand
Vitae Enim Vitae Scientific, Inc.
Lot Codes / Batch Numbers
Lot #: a) 20VPSI007, Exp 3/31/2022, 20VPSI015, Exp 5/30/2022, 20VPSI018, Exp 6/1/2022, 20VPSI032, Exp 11/30/2022, 21VPSI002, 21VPSI003, Exp 1/31/2023, 21VPSI006, Exp 3/31/2023, 21VPSI012, 21VPSI020, Exp 5/31/2023, 21VPSI035, Exp 7/31/2023, 21VPSI037, 21VPSI038, Exp 8/31/2023, 21VPSI043, 21VPSI044, Exp 10/31/2023, 21VPSI050, 21VPSI051, Exp 11/30/2023, 22VPSI004, Exp 7/31/2024, 22VPSI006, Exp 8/31/2024, b) 20VPSI008, Exp 3/31/2022, 20VPSI019, Exp 6/30/2022, 21VPSI050, Exp 11/30/2023
Products Sold
Lot #: a) 20VPSI007, Exp 3/31/2022; 20VPSI015, Exp 5/30/2022; 20VPSI018, Exp 6/1/2022; 20VPSI032, Exp 11/30/2022; 21VPSI002, 21VPSI003, Exp 1/31/2023; 21VPSI006, Exp 3/31/2023; 21VPSI012, 21VPSI020, Exp 5/31/2023; 21VPSI035, Exp 7/31/2023; 21VPSI037, 21VPSI038, Exp 8/31/2023; 21VPSI043, 21VPSI044, Exp 10/31/2023; 21VPSI050, 21VPSI051, Exp 11/30/2023; 22VPSI004, Exp 7/31/2024; 22VPSI006, Exp 8/31/2024; b) 20VPSI008, Exp 3/31/2022; 20VPSI019, Exp 6/30/2022; 21VPSI050, Exp 11/30/2023,
Vitae Enim Vitae Scientific, Inc. is recalling PHENOBARBITAL Sodium Injection, USP, 65mg/mL, packaged as a) 25 x 1 mL Vials per box (NDC 42494-415- due to Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026